Display Single Record

FOI Request

Disclosure ID
FOI/06346
Request Date
October 9, 2023
Subject
Migraine
Description

A. We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine. Could you please answer the following:

-Does the trust commission/fund Botox treatment for migraine (Y/N)?
-Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?
-Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?
-In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.

B. How many patients have been treated with the following drugs in the past 4 months:
-Atogepant (Aquipta) – any disease
-Erenumab (Aimovig) – any disease
-Eptinezumab (Vyepti) – any disease
-Fremanezumab (Ajovy) – any disease
-Galcanezumab (Emgality) – any disease
-Rimegepant (Vydura) – any disease
-Botulinum Toxin (i.e., Botox, Dysport, Xeomin) – migraine ONLY

Response

A. I can confirm neurology services are not provided by our Trust please contact Lancashire Teaching Hospitals.

B. How many patients have been treated with the following drugs in the past 4 months:

 

Atogepant (Aquipta) – any disease 0
Erenumab (Aimovig) – any disease 0
Eptinezumab (Vyepti) – any disease 0
Fremanezumab (Ajovy) – any disease 0
Galcanezumab (Emgality) – any disease 0
Rimegepant (Vydura) – any disease 0
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) – migraine ONLY Our Trust does not record drug use with respect to clinical indication. To retrieve this information would require a manual trawl of patient case notes which would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).
Attachment 1
Attachment 2
Attachment 3
Attachment 4
Attachment 5
Attachment 6
Attachment 7
Attachment 8
Attachment 9